Genmab AS (NAS:GMAB)
$ 23.12 -0.02 (-0.09%) Market Cap: 14.68 Bil Enterprise Value: 12.55 Bil PE Ratio: 19.09 PB Ratio: 3.24 GF Score: 88/100

Genmab A/S at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 05:00PM GMT
Release Date Price: $40.31 (-6.73%)
James Daniel Gordon
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning. I'm James Gordon, JPMorgan European Pharma and Biotech analyst. And today, I've got the pleasure of introducing the Genmab presentation. So you're going to hear from Genmab's CEO, Jan van de Winkel, and then we can have a Q&A here afterwards for the further 20 minutes. Thanks a lot for joining us today, Jan. Looking forward to the presentation.

Jan G.J. van de Winkel;S;Co;Founder
Genmab A;President & CEO

/-- -

Thank you very much, James. It's really a pleasure to join you all again at the annual JPMorgan Healthcare Conference as we kick off 2023. So slides from today's presentation will be available for download at our website immediately after the event. Let's get started. I think I can do that myself.

Forward-looking statements. As you are aware, this presentation may contain forward-looking statements and as such, contain certain risks and uncertainties, as you're all familiar with.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot